A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability and Efficacy of the CCR1 Antagonist ZK 811752, Given Orally in a Dose of 600 mg Three Times Daily, for the Treatment of Endometriosis Over 12 Weeks.

Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability and Efficacy of the CCR1 Antagonist ZK 811752, Given Orally in a Dose of 600 mg Three Times Daily, for the Treatment of Endometriosis Over 12 Weeks.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2016

At a glance

  • Drugs SHT 04268H (Primary)
  • Indications Endometriosis; Pain
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 31 Oct 2012 Planned number of patients added (118) as reported by European Clinical Trials Database record.
    • 20 May 2009 Additional locations (Czech Republic, Denmark, France) identified as reported by ClinicalTrials.gov.
    • 20 May 2009 Bayer added as trial sponsor, trial affiliate and lead trial centre as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top